Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján

Translated title of the contribution: Change of therapeutic algorithm in sclerosis multiplex based on two case reports

Tamás Biernacki, K. Bencsik, Zsigmond Tamás Kincses, Dániel Sandi, Zsanett Fricska-Nagy, Péter Faragó, L. Vécsei

Research output: Contribution to journalArticle

Abstract

The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.

Original languageHungarian
Pages (from-to)381-387
Number of pages7
JournalIdeggyogyaszati Szemle
Volume70
Issue number11-12
DOIs
Publication statusPublished - Nov 30 2017

Fingerprint

Sclerosis
Therapeutic Uses
Therapeutics
alemtuzumab

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján. / Biernacki, Tamás; Bencsik, K.; Kincses, Zsigmond Tamás; Sandi, Dániel; Fricska-Nagy, Zsanett; Faragó, Péter; Vécsei, L.

In: Ideggyogyaszati Szemle, Vol. 70, No. 11-12, 30.11.2017, p. 381-387.

Research output: Contribution to journalArticle

Biernacki, Tamás ; Bencsik, K. ; Kincses, Zsigmond Tamás ; Sandi, Dániel ; Fricska-Nagy, Zsanett ; Faragó, Péter ; Vécsei, L. / Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján. In: Ideggyogyaszati Szemle. 2017 ; Vol. 70, No. 11-12. pp. 381-387.
@article{d50329f4b46542ce8ce634238be07065,
title = "Ter{\'a}pi{\'a}s algoritmus v{\'a}ltoz{\'a}sa sclerosis multiplexben k{\'e}t esettanulm{\'a}ny alapj{\'a}n",
abstract = "The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.",
keywords = "Alemtuzumab, Benign MS, Case report, Sclerosis multiplex, Therapeutic guideline",
author = "Tam{\'a}s Biernacki and K. Bencsik and Kincses, {Zsigmond Tam{\'a}s} and D{\'a}niel Sandi and Zsanett Fricska-Nagy and P{\'e}ter Farag{\'o} and L. V{\'e}csei",
year = "2017",
month = "11",
day = "30",
doi = "10.18071/isz.70.0381",
language = "Hungarian",
volume = "70",
pages = "381--387",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "11-12",

}

TY - JOUR

T1 - Terápiás algoritmus változása sclerosis multiplexben két esettanulmány alapján

AU - Biernacki, Tamás

AU - Bencsik, K.

AU - Kincses, Zsigmond Tamás

AU - Sandi, Dániel

AU - Fricska-Nagy, Zsanett

AU - Faragó, Péter

AU - Vécsei, L.

PY - 2017/11/30

Y1 - 2017/11/30

N2 - The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.

AB - The aim of our case reports is to demonstrate the therapeutic use and possibilities one has with alemtuzumab, should it be used either as a first or second line therapy. Our first patient's disease in the beginning seemed to be benign. It was not the case however, over several years the diesase showed high activity both radiologically and clinically, she was treated with alemtuzumab as part of an esclationbased therapeutic strategy. The second patient's disease on the other hand showed formidable activity since the very beginning both radiologically and clinically. Therefore we were facing a very disastrous prognosis on the long run, accordingly he received alemtuzumab treatment very early into his illness.

KW - Alemtuzumab

KW - Benign MS

KW - Case report

KW - Sclerosis multiplex

KW - Therapeutic guideline

UR - http://www.scopus.com/inward/record.url?scp=85037650229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037650229&partnerID=8YFLogxK

U2 - 10.18071/isz.70.0381

DO - 10.18071/isz.70.0381

M3 - Article

VL - 70

SP - 381

EP - 387

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 11-12

ER -